New study aims to cut opioid use after breast cancer surgery

NCT ID NCT06938581

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study tests whether an Enhanced Recovery After Surgery (ERAS) protocol can reduce opioid prescriptions and pain after breast conserving surgery. 260 breast cancer patients will be randomly assigned to receive either the ERAS protocol or standard care. The ERAS protocol includes carbohydrate drinks and pain medications before surgery, plus optional anti-nausea drugs. Researchers will track opioid use, pain scores, recovery room time, and nausea medication needs.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
ERAS protocol (carbohydrate drinks, acetaminophen, celecoxib, and optional anti-nausea medications)
What this could lead to
If it works, this could provide a standard way to reduce opioid use and improve recovery after breast conserving surgery.
What could go wrong
This is a single-center trial with 260 participants, so results may not apply to all patients. The protocol involves multiple medications, which may cause side effects or not significantly reduce opioid use.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BREAST CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • University of Nebraska Medical Center

    RECRUITING

    Omaha, Nebraska, 68198, United States

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.